Anaerobic threshold responder analysis

Slides:

Advertisements

Similar presentations

Cardiac Resynchronization Heart Failure Study Cardiac Resynchronization Heart Failure Study Presented at American College of Cardiology Scientific Sessions.

Advertisements

ACC.09/i2 Summit Clinical Trial Summary Slides Peak troponin-I ng/ml ABOARD Peak troponin-I: 2.1 vs. 1.7 ng/ml, p = 0.70 No.

Protecting the heart and the kidney: Implications from the SHARP trial Dr. Christina Reith University of Oxford United Kingdom.

Chronicle Offers Management to Patients with Advanced Signs and Symptoms of Heart Failure Presented at American College of Cardiology Scientific Sessions.

Copyleft Clinical Trial Results. You Must Redistribute Slides SEISMIC Trial The Safetyand Effects of Implanted (Autologous) Skeletal Myoblasts (MyoCell)

SOLVD (Studies of Left Ventricular Dysfunction)

Sudden Cardiac Death in Heart Failure Trial Presented at American College of Cardiology Scientific Sessions 2004 Presented by Dr. Gust H. Bardy SCD-HeFTSCD-HeFT.

Treatment of Heart Failure: Beyond Medical Therapy

Presenter Disclosure Information John F. Beshai, MD RethinQ Trial Results Disclosures Information: The following relationships exist related to this presentation:

Target Study Cardiac resynchronization therapy (CRT) is an established treatment for advanced heart failure symptoms, impaired LV systolic function, and.

RALES: Randomized Aldactone Evaluation Study Purpose To determine whether the aldosterone antagonist spironolactone reduces mortality in patients with.

S ystolic H eart failure treatment with the I f inhibitor ivabradine T rial Efficacy and safety of ivabradine in patients with severe chronic systolic.

BEST: Beta-blocker Evaluation Survival Trial Purpose To determine whether the β-blocker bucindolol reduces morbidity and mortality in patients with advanced.

IRIS Post-hoc Analysis Background IRIS compared the safety and efficacy of early ICD implantation with medical treatment alone in 898 patients at high.

SMMART-HF Surgery vs. Medical Treatment Alone for Patients with Significant MitrAl RegurgitaTion & Non-Ischemic Congestive Heart Failure Duke Heart Failure.

CIBIS II Cardiac Insufficiency Bisoprolol Study

The Studies of Oral Enoximone Therapy in Advanced Heart Failure ESSENTIALESSENTIAL Presented at The European Society of Cardiology Congress 2005 Presented.

Continuous Positive Airway Pressure for Heart Patients with Central Sleep Apnea Presented at American College of Cardiology Scientific Sessions 2005 Presented.

Relationship of background ACEI dose to benefits of candesartan in the CHARM-Added trial.

STICH CABG Objective To determine whether surgery plus medical management or medical management alone improve outcomes in CABG patients Study Design 1212.

Prospective Evaluation of EECP in Congestive Heart Failure (PEECH) Trial PEECH Trial Presented at The American College of Cardiology Scientific Sessions.

Effect of Spironolactone on Diastolic Function and Exercise Capacity in Patients with Heart Failure with preserved Ejection Fraction Effect of Spironolactone.

Date of download: 6/3/2016 Copyright © The American College of Cardiology. All rights reserved. From: Risk Assessment and Comparative Effectiveness of.

Ten Year Outcome of Coronary Artery Bypass Graft Surgery Versus Medical Therapy in Patients with Ischemic Cardiomyopathy Results of the Surgical Treatment.

Date of download: 6/25/2016 Copyright © 2016 American Medical Association. All rights reserved. From: BNP-Guided vs Symptom-Guided Heart Failure Therapy:

The African-American Heart Failure Trial (A-HeFT)

Date of download: 7/8/2016 Copyright © The American College of Cardiology. All rights reserved. From: Tolerability and efficacy of carvedilol in patients.

Radiofrequency Ablation as Initial Therapy in Paroxysmal Atrial Fibrillation Jens Cosedis Nielsen, M.D., D.M.Sc., Arne Johannessen, M.D., D.M.Sc., Pekka.

From: Cost-Effectiveness of Sacubitril-Valsartan Combination Therapy Compared With Enalapril for the Treatment of Heart Failure With Reduced Ejection Fraction.

ESC 2016 Congress Highlight : ESC guidelines 2016 and what’s new in Heart failure ? Thomas MERCIER.

American College of Cardiology Presented by Dr. Stuart J. Connolly

PRISM-PLUS: Demographics of Patients With Diabetes

Rationale and design of a randomized clinical trial to assess the safety and efficacy of frequent optimization of cardiac resynchronization therapy: The.

O’Connor Efficacy and Safety of Exercise Training as a Treatment Modality in Patients With Chronic Heart Failure: Results of A Randomized Controlled.

Optimal Pacing for Right Ventricular and Biventricular Devices

Introduction: Alarming Statistics Causes of Death in Prevalent Dialysis Patients,

Equipoise ”Balance of forces or interests”

The American Heart Association

Neurostimulation for the Management of Medication-Resistant Epilepsy

Canadian Cardiovascular Society Guidelines on the Use of Cardiac Resynchronization Therapy: Evidence and Patient Selection Derek V. Exner, MD, MPH, David.

INOVATE-HF Trial design: Patients with heart failure (HF) were randomized to device implant for vagus nerve stimulation (n = 436) versus optimal medical.

OptiLink HF Trial design: Patients with heart failure who underwent implantation of an ICD were randomized to telemonitoring (n = 505) vs. usual care (n.

PARADIGM-HF Trial design: Participants with NYHA class II-IV and LVEF ≤40% were randomized to LCZ mg twice daily (n = 4,187) vs. enalapril 10 mg.

Study Design Patients with LBBB and LV dysfunction

SIGNIFY Trial design: Participants with stable coronary artery disease without clinical heart failure and resting heart rate >70 bpm were randomized to.

Modified Rankin score 0-2

CIBIS II: Cardiac Insufficiency Bisoprolol Study II

PROCAMIO Trial design: Patients with hemodynamically stable wide complex monomorphic tachycardia were randomized 1:1 to either intravenous procainamide.

PDE5 inhibitor sildenafil in the treatment of heart failure: A meta-analysis of randomized controlled trials Xiao-Dong Zhuang, Ming Long, Fei Li, Xun.

Surgical Experience and Long-term Results of Baroreflex Activation Therapy for Heart Failure With Reduced Ejection Fraction Fred A. Weaver, MD, William.

BAT for HFrEF Trial design: Patients with chronic systolic HF were randomized in a 1:1 fashion to either baroreceptor activation therapy (BAT) or control.

ALBATROSS Trial design: Patients with MI without heart failure were randomized to an IV bolus of potassium canrenoate 200 mg as early as possible, then.

(p-value between groups = 0.59)

ATHENA-HF Trial design: Patients with acute heart failure were randomized to spironolactone 100 mg daily (n = 182) vs. placebo/low-dose spironolactone.

TACTICS-HF Trial design: Patients with acute heart failure (reduced or preserved ejection fraction) were randomized to tolvaptan 30 mg at 0, 24, and 48.

Impedence-guided management

Iron Deficiency in Heart Failure

CHAMPION Trial design: Patients with recent hospitalization for heart failure were implanted with a pulmonary artery pressure monitor and randomized so.

Background. Current Perspectives on the Management of Iron Deficiency in Chronic Heart Failure.

Metoprolol for AR Trial design: Patients with chronic asymptomatic severe aortic regurgitation (AR) were randomized to metoprolol CR/XL 200 mg or matching.

The FAIR-HF Trial Reference

TRUE-AHF Trial design: Patients with acute decompensated heart failure were randomized in a 1:1 fashion to either early ularitide infusion (within 12 hours)

DENERHTN Trial design: Patients with resistant hypertension were randomized to renal denervation plus standardized stepped-care antihypertensive treatment.

MOMENTUM 3 Trial design: Patients with advanced heart failure were randomized to a centrifugal-flow pump (n = 152) vs. an axial-flow pump (n = 142). Results.

MOOD-HF Trial design: Patients with chronic systolic heart failure and comorbid depression were randomized to escitalopram (n = 185) vs. placebo (n = 187).

Surgical Experience and Long-term Results of Baroreflex Activation Therapy for Heart Failure With Reduced Ejection Fraction Fred A. Weaver, MD, William.

HF Definition. Why and How Should We Be Treating Patients With Heart Failure With Preserved Ejection Fraction?

William T. Abraham et al. JCHF 2018;j.jchf

CIRCUS Trial design: Patients with anterior STEMI were randomized to IV cyclosporine 2.5 mg/kg (n = 475) vs. placebo (n = 495) immediately before coronary.

Stepwise treatment of patients with symptomatic (NYHA II–IV) heart failure with reduced ejection fraction. Stepwise treatment of patients with symptomatic.

Presentation transcript:

Anaerobic threshold responder analysis FIX-HF-5 Trial design: Patients with NYHA III or IV heart failure and narrow QRS were randomized to cardiac contractility modulation plus optimal medical therapy (n = 215) vs. optimal medical therapy alone (n = 213). Results (p = 0.093) Anaerobic threshold responder analysis: 17.6% with treatment vs. 11.7% with control (p = 0.093) Peak VO2 improved by 0.65 ml/kg/min with treatment (p = 0.024) Quality of life improved by -9.7 points with treatment (p < 0.0001) 17.6 % 11.7 Conclusions Among patients with advanced heart failure, low ejection fraction, and narrow QRS, cardiac contractility modulation failed to improve the primary efficacy outcome, anaerobic threshold Cardiac contractility modulation did improve peak VO2 and quality of life Anaerobic threshold responder analysis Cardiac contractility modulation Control Presented by Dr. William Abraham at ACC.09/i2, Orlando, FL